Looking forward to AAIC 2022 with science director Chris Weber

22 July 2022

alzheimer-s-neurology-brain-dementia-big

One year on from the historic approval of the first new Alzheimer’s med in decades, the world’s largest event focused on the disease is set to take place in San Diego, California.

The annual Alzheimer's Association International Conference (AAIC) kicks off on July, and 31 AAIC leaders are emphasizing research into the connection between diversity and dementia, as well as the impact of diet, income and cardio-vascular factors on neurological health.

Chris Weber, the Alzheimer’s Association’s director of global science initiatives, spoke with The Pharma Letter in the runup to the event.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK